KRAS and colorectal cancer: In various tumor-bearing mouse model, such as KRAS-mutant colorectal cancer (158, 159), BRAFV600E-mutant melanoma (160), and triple-negative breast cancer (161), the inhibition of MEK demonstrated better efficacy in combining with antibodies targeting PD-1 or PD-L1, compared to single agent.